Hypertension: Silent Killer
HTN is the leading modifiable risk factor for cardiovascular disease, stroke, and kidney failure. Most patients are asymptomatic — opportunistic screening at every GP visit is essential. Treating to target reduces stroke risk by 35–40% and MI risk by 20–25%.
Based on ISH 2020 & ESH 2023 guidelines. Diagnosis requires 2+ separate visits unless crisis.
Reassess in 1–2 years. Promote lifestyle habits.
Lifestyle modification. Reassess in 3–6 months.
Lifestyle modification ± pharmacotherapy based on CVD risk.
Lifestyle modification + pharmacotherapy. Reassess in 1 month.
Urgent assessment. Differentiate urgency vs emergency.
From the Blog
Hypertension Management in General Practice: A Complete 2025 Guide
NICE NG136 · ABCD Algorithm · Resistant HTN
Cardiovascular Risk Assessment: QRISK3, Statins & Beyond
QRISK3 · Statin Thresholds · Lipid Targets
Atrial Fibrillation: Detection, Anticoagulation & Rate Control
CHA₂DS₂-VASc · DOACs · Rate Control
Clinical Algorithms
More decision flowcharts
Lab Reference
Renal & metabolic panels
Drug Database
Full dosing & interactions
Based on ISH 2020, ESH/ESC 2023, NICE NG136, JNC8 guidelines. Always individualize management. Refer complex cases to a specialist.